Ethyol Related Published Studies
Well-designed clinical trials related to Ethyol (Amifostine)
Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. [2009.09]
Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer. [2008.10.01]
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. [2007.09]
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer. [2006.08.01]
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. [2006.03.01]
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. [2005.11.15]
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. [2005.10]
Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. [2005.09]
Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. [2005.06.01]
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. [2005.05]
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. [2005.04.01]
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. [2005.04]
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. [2005.04]
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01. [2004.12]
A randomized phase II trial of amifostine for head and neck irradiation in lymphoma. [2004.12]
A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. [2004.09]
A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. [2004.07]
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. [2004.04.01]
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. [2004.04]
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. [2004.03]
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. [2003.12]
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. [2003.12]
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. [2003.10.01]
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. [2003.08]
Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. [2003.07.15]
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. [2003.07]
Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? [2003.06]
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. [2003.05.01]
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. [2003.04]
Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. [2003.03]
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. [2003]
Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. [2002.12]
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. [2002.12]
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. [2002.12]
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. [2002.12]
Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor. [2002.12]
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. [2002.05]
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. [2002.03.01]
New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. [2002.02]
Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. [2002.01]
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. [2002.01]
A randomized phase II study of amifostine used as stem cell protectant in non-hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant. [2001.12]
Alteration of radiation-induced hematotoxicity by amifostine. [2001.11.15]
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. [2001.11.15]
Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. [2001.08]
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. [2001.02.02]
PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial. [2001.02]
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. [2001.01.05]
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. [2001]
Protective effect of amifostine on dental health after radiotherapy of the head and neck. [2000.12.01]
Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. [2000.11.01]
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. [2000.10.01]
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. [2000.08]
Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. [2000.06]
Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study. [2000.06]
A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. [2000.03.15]
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. [2000.01]
Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? [1999.11]
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial] [1999.11]
[Alteration of radiation-induced hematotoxicity by amifostine (ethyol)] [1999.11]
Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. [1999.11]
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. [1999.10]
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. [1999.06]
Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. [1998.11]
Amifostine in reducing cisplatin toxicity. [1998.10]
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. [1998.05]
Radiochemotherapy with amifostine cytoprotection for head and neck cancer. [1998.03]
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. [1997.09.15]
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). [1997.09]
Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. [1997.07]
[Amifostine: current and future applications in cytoprotection] [1996.09]
Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. [1996.08]
Use of amifostine in bone marrow purging. [1996.08]
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. [1996.07]
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. [1995.12]
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. [1994.06.01]
Well-designed clinical trials possibly related to Ethyol (Amifostine)
Interventions for preventing neuropathy caused by cisplatin and related compounds. [2007.01.24]
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). [2003.12]
[Amifostin in protection of kidney from cisplatinum injury] [2002.01]
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study] [2001.05]
[Experiences with sodium selenite in treatment of acute and late adverse effects of radiochemotherapy of head-neck carcinomas. Cytoprotection Working Group in AK Supportive Measures in Oncology Within the scope of MASCC and DKG] [1999.10.15]
Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation. [1999.05.15]
Choices of methodology in pharmacoeconomics studies. [1999.04]
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. [1994]
New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. [1993]
Use of radiation with or without WR-2721 in advanced rectal cancer. [1992.06.01]
Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. [1992]
Other research related to Ethyol (Amifostine)
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. [2009.10.07]
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. [2009.10.07]
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. [2009.10.01]
Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits. [2009.09.17]
Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report. [2009.07.15]
Cytoprotective effects of amifostine in the treatment of childhood malignancies. [2009.07]
Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats. [2009.05]
Computed Tomography Assessment of Lung Density in Patients With Lung Cancer Treated With Accelerated Hypofractionated Radio-Chemotherapy Supported With Amifostine. [2009.04.03]
Evaluation of the possible benefits of post-radiotherapy surgery after concomitant chemoradiotherapy with a new radio-sensitizing regimen (irinotecan / CPT-11, interferon A2b and amifostine) for advanced-stage cervical carcinoma. Preliminary results of a pilot phase-II study. [2009.04]
The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. [2009.03]
Effects of amifostine administration prior to irradiation to the submandibular gland in mice: autoradiographic study using 3H-leucine. [2009.02]
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. [2009.02]
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. [2008.12.01]
The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study. [2008.11.30]
|
